抗肿瘤复方药物研发现状与挑战

doi:10.19803/j.1672-8629.20240274

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 961-966.
DOI: 10.19803/j.1672-8629.20240274

• 复方与联合用药安全性评价专栏（二） • 上一篇下一篇

抗肿瘤复方药物研发现状与挑战

江海燕¹, 周甜雨², 范潇予¹, 李万芳^1,3, 包捷^1,3, 靳洪涛^1,3,4,*

¹中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京 100050;
²陕西中医药大学药学院,陕西咸阳 712046;
³北京协和建昊医药技术开发有限责任公司,北京 100176;
⁴国家药品监督管理局创新药物安全研究与评价重点实验室,北京 102206

收稿日期:2024-04-28 出版日期:2024-09-15 发布日期:2024-09-14
通讯作者: ^*靳洪涛,男,研究员·博导,药物毒理学。E-mail：jinhongtao@imm.ac.cn
作者简介:江海燕,女,在读博士,药物毒理学。
基金资助:
国家自然科学基金资助项目（82074104、22177134）; 中国毒理学会临床毒理课题（CST2021CT101）

Challenges to the current development of fixed-dose antitumor drug combinations

JIANG Haiyan¹, ZHOU Tianyu², FAN Xiaoyu¹, LI Wanfang^1,3, BAO Jie^1,3, JIN Hongtao^1,3,4,*

¹New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
²College of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang Shanxi 712046, China;
³Beijing Union-Genius Pharmaceutical Technology Development Co., Ltd., Beijing 100176, China;
⁴NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drug, Beijing 102206, China

Received:2024-04-28 Online:2024-09-15 Published:2024-09-14

摘要/Abstract

摘要： 目的综述复方药物在抗肿瘤药物研发中的特点,以期为抗肿瘤复方药物研发提供参考。方法通过检索国内外相关文献及数据库,对已上市的抗肿瘤复方药物及近3年美国食品药品监督管理局（FDA）批准的药物联合治疗方案进行分析。结果目前上市的抗肿瘤复方药物通过多靶点协同作用或改善给药途径等方式,可提高药物治疗效果,改善患者依从性并降低药物毒性作用。结论抗肿瘤复方药物具有治疗优势,但在研发过程中仍面临诸多挑战,未来人工智能可为复方药物研发提供技术支撑和创新动力。

关键词: 复方药物, 肿瘤治疗, 多靶点, 联合用药, 药物研发

Abstract: Objective To summarize the characteristics of fixed-dose combinations in the development of antitumor drugs so as to provide references for the development of related combinations. Methods By searching for relevant literature from domestic and overseas databases, the marketed fixed-dose antitumor drug combinations and combination therapies approved by the US FDA in the past three years were analyzed. Results The marketed fixed-dose antitumor drug combinations could significantly improve the therapeutic effects of drugs, improve patient compliance and reduce drug toxicity through multi-target synergistic effects or by improving drug delivery routes. Conclusion Fixed-dose antitumor drug combinations enjoy significant advantages in clinic but still face many challenges in the course of development. In the future, artificial intelligence can provide strong technical support and innovation incentives for the development of drugs.

Key words: combination drug, tumor therapy, multi-target, combination regimen, drug development

中图分类号:

R916
R979.1

江海燕, 周甜雨, 范潇予, 李万芳, 包捷, 靳洪涛. 抗肿瘤复方药物研发现状与挑战[J]. 中国药物警戒, 2024, 21(9): 961-966.

JIANG Haiyan, ZHOU Tianyu, FAN Xiaoyu, LI Wanfang, BAO Jie, JIN Hongtao. Challenges to the current development of fixed-dose antitumor drug combinations[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 961-966.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240274

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/961

参考文献

[1] LUO GA, LIANG QL, LIU QF, et al.Prospect on the composite drugs innovation system[J]. World Science and Technology-Modernization of Traditional Chinese Medicine(世界科学技术-中医药现代化), 2009, 11(1): 3-10.
[2] YUAN BX, CHEN LN, WANG B.Strategy of fixed-dose combination innovative development[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2013, 18(10): 1175-1181.
[3] YAO W, WAN Z.Clinical research progress and application prospect of polypill[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine(中国循证心血管医学杂志), 2012, 4(6): 491-493.
[4] WU MY, XU W, WANG HY.Dosage regimen selection and application for monoclonal antibody in oncology[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2019, 35(19): 2471-2475.
[5] QIAN SY, KANG CL.Consideration about compound medicine[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2015, 31(13): 1335-1337.
[6] PAIK J.Nivolumab plus relatlimab: first approval[J]. Drugs, 2022, 82(8): 925-931.
[7] AGGARWAL V, WORKMAN CJ, VIGNALI DAA.LAG-3 as the third checkpoint inhibitor[J]. Nat Immunol, 2023, 24(9): 1415-1422.
[8] CHI KN, RATHKOPF D, SMITH MR, et al.Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2023, 41(18): 3339-3351.
[9] MAYER RJ, VAN CUTSEM E, FALCONE A, et al.Randomized trial of TAS-102 for refractory metastatic colorectal cancer[J]. NEngl J Med, 2015, 372(20): 1909-1919.
[10] CHIDA K, KOTANI D, NAKAMURA Y, et al.Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study[J]. Ther Adv Med Oncol, 2021, 13: 17588359211009143.
[11] HUGHES MS, LENTZSCH S.Safety and efficacy of subcutaneous daratumumab in systemic AL amyloidosis[J]. Ther Clin Risk Manag, 2023, 19: 1063-1074.
[12] TAN AR, IM SA, MATTAR A, et al.Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study[J]. Lancet Oncol, 2021, 22(1): 85-97.
[13] RINI BI, SIGNORETTI S, CHOUEIRI TK, et al.Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma[J]. J Immunother Cancer, 2022, 10(12): e005445.
[14] TYKODI SS, GORDAN LN, ALTER RS, et al.Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial[J]. J Immunother Cancer, 2022, 10(2): e003844.
[15] ABEDI KB, ABBASI A, GHASEMI DN, et al.Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): a new era in tumor immunotherapy[J]. Int Immunopharmacol, 2022, 113(Pt A): 109365.
[16] NIKOO M, RABIEE F, MOHEBBI H, et al.Nivolumab plus ipilimumab combination therapy in cancer: current evidence to date[J]. Int Immunopharmacol, 2023, 117: 109881.
[17] LU L, ZHAN M, LI XY, et al.Clinically approved combination immunotherapy: current status, limitations, and future perspective[J]. Curr Res Immunol, 2022, 3: 118-127.
[18] LEE WS, YANG H, CHON HJ, et al.Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity[J]. Exp Mol Med, 2020, 52(9): 1475-1485.
[19] ALLEN E, JABOUILLE A, RIVERA LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation[J]. Sci Transl Med, 2017, 9(385): eaak9679.
[20] LORD CJ, ASHWORTH A.PARP inhibitors: synthetic lethality in the clinic[J]. Science(New York, NY), 2017, 355(6330): 1152-1158.
[21] LIU JF, BARRY WT, BIRRER M, et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study[J]. Lancet Oncol, 2014, 15(11): 1207-1214.
[22] LIU JF, BRADY MF, MATULONIS UA, et al.Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial[J]. J Clin Oncol, 2022, 40(19): 2138-2147.
[23] PENSON RT, VALENCIA RV, CIBULA D, et al.Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial[J]. J Clin Oncol, 2020, 38(11): 1164-1174.
[24] JANCZURA M, SIP S, CIELECKA-PIONTEK J.The development of innovative dosage forms of the fixed-dose combination of active pharmaceutical ingredients[J]. Pharmaceutics, 2022, 14(4): 834.
[25] GOYANES A, DET-AMORNRAT U, WANG J, et al.3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems[J]. J Control Release, 2016, 234: 41-48.
[26] PIETRZAK K, ISREB A, ALHNAN MA.A flexible-dose dispenser for immediate and extended release 3D printed tablets[J]. Eur J Pharm Biopharm, 2015, 96: 380-387.
[27] KUENZI BM, PARK J, FONG SH, et al.Predicting drug response and synergy using a deep learning model of human cancer cells[J]. Cancer Cell, 2020, 38(5): 672-684.
[28] YANG J, XU Z, WU WKK, et al.GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction[J]. J Am Med Inform Assoc, 2021, 28(11): 2336-2345.

抗肿瘤复方药物研发现状与挑战

Challenges to the current development of fixed-dose antitumor drug combinations

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	徐泽澳, 江海燕, 范潇予, 李万芳, 包捷, 徐成, 靳洪涛. 抗神经退行性疾病复方药物研究进展[J]. 中国药物警戒, 2024, 21(9): 967-972.
[2]	孙思曼, 江海燕, 范潇予, 李万芳, 包捷, 王川, 靳洪涛. 抗获得性免疫缺陷综合征复方制剂研究进展[J]. 中国药物警戒, 2024, 21(9): 978-984.
[3]	申雪, 江海燕, 范潇予, 李万芳, 包捷, 何博赛, 靳洪涛. 联合用药治疗肝纤维化的研究概况与展望[J]. 中国药物警戒, 2024, 21(9): 985-990.
[4]	赵晓璐, 高晓阳, 张春艳, 李明奇, 马月宏. PPARγ在肝纤维化进程中的影响及其配体药物研发进展[J]. 中国药物警戒, 2024, 21(6): 716-720.
[5]	张健, 张伶俐, 李歆. 424例替雷利珠单抗致免疫相关不良事件分析[J]. 中国药物警戒, 2024, 21(4): 435-439.
[6]	郭益俊, 陈霞, 孟萍. 141例靶向抗肿瘤口服药品不良反应分析[J]. 中国药物警戒, 2024, 21(10): 1137-1142.
[7]	严亦舒, 赵岩, 卢天公, 孙震晓. 大黄素-8-O-β-D-葡萄糖苷联合紫杉醇抑制人乳腺癌细胞活力及侵袭转移的研究[J]. 中国药物警戒, 2023, 20(7): 728-734.
[8]	王淑伟, 殷进军, 王冰, 宋彩萍, 杨福俊. 阿昔替尼片联合特瑞普利单抗治疗晚期肾癌致视网膜中央动脉阻塞1例分析[J]. 中国药物警戒, 2023, 20(7): 825-828.
[9]	罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504.
[10]	杜莹, 谢雁鸣, 王连心, 耿洪娇, 李向杰. 真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析[J]. 中国药物警戒, 2023, 20(3): 296-300.
[11]	徐帅, 张玲, 赵玉清, 杨一点, 卞昊宇, 张立平. 中药多靶点干预代谢综合征血管内皮损伤研究进展[J]. 中国药物警戒, 2023, 20(3): 353-359.
[12]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[13]	孙静, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 崔晓兰. 疏风解毒胶囊联合左氧氟沙星治疗多重耐药铜绿假单胞菌感染性小鼠肺炎的作用研究[J]. 中国药物警戒, 2023, 20(1): 52-56.
[14]	苏鑫鑫, 赵晓晓, 谢雁鸣. 榄香烯乳注射液治疗肝癌患者的真实世界联合用药分析[J]. 中国药物警戒, 2022, 19(9): 929-934.
[15]	黄艳丽, 谢雁鸣, 王连心, 孙粼希, 刘峘, 庄鋆妮. 真实世界老年患者使用刺五加注射液的临床分析[J]. 中国药物警戒, 2022, 19(9): 935-939.